NFL Biosciences SAS

NFL Biosciences SA is a biotechnology company based in Castelnau-le-Lez, France, that develops botanical drugs. Its pipeline includes NFL-101, a drug candidate for smoking cessation that is in the CESTO II Phase 2 study, and NFL-301, a preclinical-stage drug candidate for reducing alcohol consumption. The company has a scientific collaboration with McLean Hospital to deepen understanding of the mechanism of action of NFL-101. NFL Biosciences SA was incorporated in 2006.